Cencora analyst targets imply upside, shares in S&P 500 healthcare focus

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 21:02.

Cencora Inc. (US15135B1017) remains closely watched on the NYSE as Wall Street analysts see further room for gains from current levels. A recent consensus overview compiled by Zacks points to an average price target of 361 dollars, implying roughly 33 percent upside from a last cited level around 270 dollars. Zacks analyst consensus on Cencora

What analysts currently expect

The Zacks summary notes that 12 short-term price targets for Cencora converge on a mean of 361 dollars, with estimates ranging from 280 to 425 dollars per share. Zacks analyst consensus on Cencora On that basis, the implied upside from a reference price of 270.32 dollars is about 33.6 percent.

The dispersion of expectations is marked, with a standard deviation of roughly 45 dollars between the individual targets according to Zacks. Zacks analyst consensus on Cencora That range reflects differing views on earnings momentum and valuation for the S&P 500 healthcare distributor compared with sector peers such as McKesson and Cardinal Health.

Recent share performance and index role

According to MarketBeat data, Cencora shares recently closed at 284.94 dollars on the NYSE, with an intraday range on 2026-06-24 between 281.11 and 288.53 dollars. MarketBeat quote overview for Cencora Over the last 50 trading days the shares have traded in a corridor between 253.20 and 327.52 dollars, indicating elevated volatility compared with some defensive healthcare names.

MarketBeat lists Cencora with the ticker COR on the NYSE and shows a 52-week span from 215.32 to 347.99 dollars. MarketBeat quote overview for Cencora With a market capitalization in the tens of billions of dollars, the company ranks as a meaningful component in broad indices such as the S&P 500, where healthcare distributors collectively provide exposure to US pharmaceutical and specialty drug flows.

How Cencora earns its money

Cencora’s core business is pharmaceutical distribution and related services. The group, formerly known as AmerisourceBergen, sources branded and generic medicines as well as specialty therapeutics and delivers them to pharmacies, hospitals, clinics and other healthcare providers across North America and selected international markets. Cencora corporate information

Beyond physical drug distribution, Cencora offers logistics, market access support and supply chain solutions for biotechnology and pharmaceutical manufacturers, helping them manage product launches, cold-chain requirements and reimbursement processes. Cencora corporate information This combination of volume-driven distribution and higher-margin service offerings is central to the company’s earnings model.

Where the shares trade today

The Cencora shares (US15135B1017) last closed on the NYSE at 284.94 dollars on 2026-06-24, according to MarketBeat data. MarketBeat quote overview for Cencora

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance. Figures and dates are based on publicly available sources cited in the text.